Lymphoma News and Features
Survival for follicular lymphoma and diffuse large B-cell lymphoma is improving in Europe.
Survivors of Hodgkin lymphoma have an increased risk for developing various late complications, including cardiovascular disease.
Late effect of Hodgkin lymphoma (HL) treatment is a 2.5-fold increased risk of coronary heart disease (CHD) in survivors.
Lenalidomide plus rituximab produced durable and long-term responses in previously untreated patients with mantle cell lymphoma.
Results from a phase 1 clinical trial suggest that pevonedistat is safe, tolerable, and has some anticancer activity.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
- Risk of Some Cancers Modestly Increased in Persons Who Had Herpes Zoster
- Blood Test Indicates Breast Cancer Tumors Developed Resistance to Hormone Treatment
- Breakthrough Advance Announced in International Blood Cancer Drug Trial
- Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
- Survival for Follicular, Diffuse Large B-cell Lymphomas Improving in Europe
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Navigation Program Tackles Cancer Care on Two Fronts
- Protein Biomarker Assays for Diagnosing Thyroid Cancer May Show Inaccurate Readings
- Cancer Prehabilitation and Rehabilitation: What Will It Take for These Services to Catch On?
- New Model for Breast Cancer Risk in Hispanic Women Is the First to be Based Exclusively on Data From Hispanic Women
- Blood Sample New Way of Detecting Cancer
- Liquid Biopsy of Cerebrospinal Fluid More Effective in Managing Brain Tumors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|